Muscarinic Agonists and Acetylcholinesterase Inhibitors — Questions

Drug Classification · Questions 1–6

Identify the pharmacological class or categorical label for each drug. Vocabulary preparation is sufficient to answer every question in this section.

Question 1

Bethanechol is classified as which of the following?

ATertiary amine direct-acting muscarinic agonist
BQuaternary ammonium direct-acting muscarinic agonist
CReversible acetylcholinesterase inhibitor
DNicotinic receptor agonist

Correct Answer

B — Quaternary ammonium direct-acting muscarinic agonist

Explanation

Bethanechol is classified as a quaternary ammonium direct-acting muscarinic agonist. Its quaternary structure gives it a permanent positive charge, which prevents it from crossing lipid membranes including the blood-brain barrier, confining its effects to peripheral muscarinic receptors.

Question 2

Pilocarpine is classified as which of the following?

AQuaternary ammonium direct-acting muscarinic agonist
BMuscarinic receptor antagonist
CReversible acetylcholinesterase inhibitor
DTertiary amine direct-acting muscarinic agonist

Correct Answer

D — Tertiary amine direct-acting muscarinic agonist

Explanation

Pilocarpine is classified as a tertiary amine direct-acting muscarinic agonist. Its tertiary amine structure means it is uncharged at physiological pH and can cross lipid membranes, giving it the potential for central nervous system penetration that distinguishes it from quaternary agents such as bethanechol.

Question 3

Edrophonium is classified as which of the following types of acetylcholinesterase inhibitor?

AReversible inhibitor with ultrashort duration due to non-covalent binding
BReversible carbamylating inhibitor with intermediate duration
CIrreversible organophosphate inhibitor
DDirect-acting muscarinic agonist

Correct Answer

A — Reversible inhibitor with ultrashort duration due to non-covalent binding

Explanation

Edrophonium is classified as a reversible acetylcholinesterase inhibitor with ultrashort duration. Unlike neostigmine and pyridostigmine, which carbamylate the enzyme active site, edrophonium binds through weak non-covalent electrostatic interactions, producing effects that begin within seconds and resolve within minutes.

Question 4

Methacholine is classified as which of the following?

ATherapeutic muscarinic agonist used for urinary retention
BReversible acetylcholinesterase inhibitor used for myasthenia gravis
CSelective muscarinic agonist used only for diagnostic bronchoprovocation
DMuscarinic receptor antagonist used for airway disease

Correct Answer

C — Selective muscarinic agonist used only for diagnostic bronchoprovocation

Explanation

Methacholine is classified as a selective muscarinic agonist with no established therapeutic use. Its only clinical role is the methacholine bronchoprovocation challenge, in which inhaled methacholine stimulates muscarinic subtype 3 receptors in airway smooth muscle to test for airway hyperresponsiveness in suspected asthma.

Question 5

Pyridostigmine is the preferred oral agent for long-term management of myasthenia gravis. Which of the following best describes its pharmacological classification?

AReversible acetylcholinesterase inhibitor with ultrashort duration due to non-covalent binding
BReversible carbamylating acetylcholinesterase inhibitor with longer duration than neostigmine
CIrreversible organophosphate acetylcholinesterase inhibitor
DDirect-acting muscarinic agonist

Correct Answer

B — Reversible carbamylating acetylcholinesterase inhibitor with longer duration than neostigmine

Explanation

Pyridostigmine is classified as a reversible carbamylating acetylcholinesterase inhibitor. It inhibits the enzyme by transferring a carbamyl group to the active site serine, producing an intermediate that recovers over hours — giving it a longer duration of action than neostigmine and making it suitable for regular oral dosing in myasthenia gravis management.

Question 6

Cevimeline is classified as which of the following?

AQuaternary ammonium muscarinic agonist used for urinary retention
BNon-selective muscarinic agonist used for glaucoma
CSelective muscarinic agonist used only for diagnostic bronchoprovocation
DTertiary amine muscarinic agonist selective for muscarinic subtype 1 and subtype 3 receptors, used for xerostomia in Sjogren syndrome

Correct Answer

D — Tertiary amine muscarinic agonist selective for muscarinic subtype 1 and subtype 3 receptors, used for xerostomia in Sjogren syndrome

Explanation

Cevimeline is classified as a tertiary amine direct-acting muscarinic agonist with selective activity at muscarinic subtype 1 and subtype 3 receptors. It was developed specifically for xerostomia in Sjogren syndrome, where its subtype selectivity and longer duration of action compared to pilocarpine offer a clinical alternative for patients who cannot tolerate pilocarpine.

Core Pharmacology · Questions 7–14

Apply your understanding of drug mechanisms, pharmacokinetics, and adverse effects. Each question requires one reasoning step.

Question 7

A patient is given bethanechol for non-obstructive urinary retention. Which of the following best explains why this drug produces no central nervous system effects at therapeutic doses?

ABethanechol is rapidly metabolized before reaching the brain
BMuscarinic receptors in the brain are insensitive to bethanechol
CBethanechol carries a permanent positive charge and cannot cross the blood-brain barrier
DBethanechol is selectively distributed to the bladder and gastrointestinal tract

Correct Answer

C — Bethanechol carries a permanent positive charge and cannot cross the blood-brain barrier

Explanation

Bethanechol is a quaternary ammonium compound, meaning it carries a permanent positive charge at physiological pH. Charged molecules cannot cross lipid membranes, including the blood-brain barrier. This structural property confines bethanechol's muscarinic agonist activity to peripheral sites, producing no central nervous system effects at therapeutic doses.

Question 8

Pilocarpine eye drops are used to treat open-angle glaucoma. Which of the following best explains the mechanism by which pilocarpine lowers intraocular pressure?

AActivation of muscarinic subtype 3 receptors contracts the ciliary muscle, improving aqueous humor drainage through trabecular outflow
BBlockade of beta-2 adrenergic receptors reduces aqueous humor production by the ciliary epithelium
CInhibition of carbonic anhydrase reduces bicarbonate secretion and aqueous humor formation
DActivation of alpha-2 adrenergic receptors reduces aqueous humor production and increases uveoscleral outflow

Correct Answer

A — Activation of muscarinic subtype 3 receptors contracts the ciliary muscle, improving aqueous humor drainage through trabecular outflow

Explanation

Pilocarpine activates muscarinic subtype 3 receptors in the eye. Contraction of the ciliary muscle pulls on the trabecular meshwork, opening the drainage channels and increasing aqueous humor outflow. The reduction in outflow resistance lowers intraocular pressure. The same muscarinic subtype 3 activation also contracts the sphincter pupillae, producing the miosis that accompanies pilocarpine use.

Question 9

Neostigmine and edrophonium both inhibit acetylcholinesterase, but edrophonium has a duration of action measured in minutes while neostigmine acts for hours. Which of the following best explains this difference?

AEdrophonium is more rapidly metabolized by plasma esterases than neostigmine
BNeostigmine has higher affinity for the acetylcholinesterase active site than edrophonium
CEdrophonium is eliminated more rapidly by the kidneys than neostigmine
DNeostigmine forms a covalent carbamyl-enzyme bond that recovers slowly, while edrophonium binds through weak non-covalent electrostatic interactions that dissipate rapidly

Correct Answer

D — Neostigmine forms a covalent carbamyl-enzyme bond that recovers slowly, while edrophonium binds through weak non-covalent electrostatic interactions that dissipate rapidly

Explanation

The duration difference between neostigmine and edrophonium is determined by their binding chemistry at the acetylcholinesterase active site. Neostigmine carbamylates the active site serine, forming a covalent bond that hydrolyzes slowly over hours before the enzyme regenerates. Edrophonium binds only through electrostatic interactions without forming any covalent bond, so it dissociates within minutes as the interaction is overcome by normal enzyme dynamics.

Question 10

When neostigmine is given to reverse non-depolarizing neuromuscular blockade after surgery, it is always co-administered with glycopyrrolate rather than atropine. Which of the following best explains why glycopyrrolate is preferred?

AGlycopyrrolate has a longer duration of action than atropine, providing more sustained muscarinic blockade
BGlycopyrrolate is a quaternary compound with the same onset speed as neostigmine and does not cross the blood-brain barrier, avoiding the transient bradycardia and central nervous system effects of atropine
CGlycopyrrolate selectively blocks muscarinic receptors at the neuromuscular junction without affecting heart rate
DGlycopyrrolate potentiates the neuromuscular blockade reversal effect of neostigmine

Correct Answer

B — Glycopyrrolate is a quaternary compound with the same onset speed as neostigmine and does not cross the blood-brain barrier, avoiding the transient bradycardia and central nervous system effects of atropine

Explanation

Glycopyrrolate is a quaternary ammonium muscarinic antagonist. Its quaternary structure gives it the same pharmacokinetic onset as neostigmine, ensuring that muscarinic blockade is present when acetylcholine begins to accumulate. Because it cannot cross the blood-brain barrier, glycopyrrolate avoids the central nervous system effects of atropine. It also avoids the transient bradycardia that can briefly precede atropine's peak peripheral muscarinic blocking effect.

Question 11

A patient with myasthenia gravis taking pyridostigmine develops cramping and diarrhea after a dose increase. Which of the following best explains the mechanism producing these adverse effects?

APyridostigmine directly stimulates nicotinic receptors in the gastrointestinal smooth muscle
BPyridostigmine irritates the gastrointestinal mucosa through a direct toxic effect
CAcetylcholine accumulation at muscarinic receptors on gastrointestinal smooth muscle increases motility and secretion
DPyridostigmine crosses the blood-brain barrier and activates central autonomic centers controlling gut motility

Correct Answer

C — Acetylcholine accumulation at muscarinic receptors on gastrointestinal smooth muscle increases motility and secretion

Explanation

Pyridostigmine inhibits acetylcholinesterase at all cholinergic synapses, including the postganglionic parasympathetic junctions in the gastrointestinal tract. Acetylcholine accumulation at muscarinic receptors on gastrointestinal smooth muscle and secretory cells increases bowel motility and secretion, producing cramping and diarrhea. These muscarinic adverse effects are dose-dependent and represent the most common reason for dose adjustment in myasthenia gravis management.

Question 12

Bethanechol is contraindicated in patients with asthma. Which of the following best explains why?

AMuscarinic receptor activation in airway smooth muscle causes bronchoconstriction, worsening airflow obstruction
BBethanechol inhibits beta-2 adrenergic receptors in the airway, reducing bronchodilation
CBethanechol crosses the blood-brain barrier and suppresses the central respiratory drive
DBethanechol reduces surfactant production in the alveoli, impairing gas exchange

Correct Answer

A — Muscarinic receptor activation in airway smooth muscle causes bronchoconstriction, worsening airflow obstruction

Explanation

Bethanechol activates muscarinic receptors including muscarinic subtype 3 receptors in airway smooth muscle. Muscarinic subtype 3 activation in the airway produces bronchoconstriction, which would worsen the airflow obstruction already present in asthma. This is the same mechanism exploited diagnostically by the methacholine bronchoprovocation challenge, and it explains why all muscarinic agonists are contraindicated in patients with reactive airway disease.

Question 13

The edrophonium test was historically used to diagnose myasthenia gravis. Which property of edrophonium makes it suitable for this diagnostic purpose?

AEdrophonium selectively acts at the neuromuscular junction without producing muscarinic adverse effects
BEdrophonium crosses the blood-brain barrier and directly activates motor neurons
CEdrophonium has a longer duration than neostigmine, providing a sustained window to observe muscle improvement
DEdrophonium has an ultrashort duration, producing a brief transient improvement in weakness that resolves completely within minutes

Correct Answer

D — Edrophonium has an ultrashort duration, producing a brief transient improvement in weakness that resolves completely within minutes

Explanation

The diagnostic utility of edrophonium depends entirely on its ultrashort duration of action. When given intravenously, edrophonium transiently increases acetylcholine at the neuromuscular junction, producing a brief measurable improvement in weakness if the deficit is caused by reduced nicotinic receptor availability — as in myasthenia gravis. Because the effect resolves completely within minutes, it serves as a clean diagnostic window without committing the patient to prolonged pharmacological effects.

Question 14

A patient with myasthenia gravis who has been stable on pyridostigmine develops acute worsening of weakness. The clinical team must determine whether this represents myasthenic crisis or cholinergic crisis. Which of the following best describes how these two conditions differ in terms of their underlying mechanism?

AMyasthenic crisis results from excess acetylcholine at the neuromuscular junction; cholinergic crisis results from insufficient acetylcholine
BMyasthenic crisis results from insufficient acetylcholine effect at the neuromuscular junction; cholinergic crisis results from excess acetylcholine from overdose of acetylcholinesterase inhibitor
CMyasthenic crisis results from new antibodies destroying nicotinic receptors; cholinergic crisis results from antibodies blocking acetylcholinesterase
DBoth crises result from the same mechanism but differ in the muscle groups affected

Correct Answer

B — Myasthenic crisis results from insufficient acetylcholine effect at the neuromuscular junction; cholinergic crisis results from excess acetylcholine from overdose of acetylcholinesterase inhibitor

Explanation

Myasthenic crisis occurs when the autoimmune destruction of nicotinic receptors progresses to the point where even maximum acetylcholine signaling cannot maintain adequate neuromuscular transmission — the patient is undertreated relative to their disease burden. Cholinergic crisis occurs when excess acetylcholinesterase inhibitor produces so much acetylcholine accumulation that the neuromuscular junction enters a depolarizing block from persistent endplate depolarization — the patient is overtreated. Both produce weakness, but the treatment is opposite: myasthenic crisis requires more acetylcholinesterase inhibitor or immunotherapy; cholinergic crisis requires withholding the drug.

Clinical Correlations · Questions 15–18

Apply pharmacological knowledge to clinical scenarios. Each vignette presents a patient situation; the question tests mechanism of action or drug selection.

Question 15

A 58-year-old man with open-angle glaucoma is started on pilocarpine eye drops. His ophthalmologist explains that the drops work by improving fluid drainage from the eye. Which of the following best explains the mechanism by which pilocarpine lowers intraocular pressure in this patient?

AMuscarinic receptor activation contracts the ciliary muscle, pulling open the trabecular meshwork and increasing aqueous humor outflow
BMuscarinic receptor activation reduces aqueous humor production by the ciliary body epithelium
CMuscarinic receptor activation dilates the pupil, reducing resistance to aqueous humor flow
DMuscarinic receptor activation inhibits carbonic anhydrase, decreasing bicarbonate and fluid secretion into the anterior chamber

Correct Answer

A — Muscarinic receptor activation contracts the ciliary muscle, pulling open the trabecular meshwork and increasing aqueous humor outflow

Explanation

Pilocarpine activates muscarinic subtype 3 receptors in the ciliary muscle of the eye. Contraction of the ciliary muscle pulls on the trabecular meshwork, widening the drainage channels and reducing resistance to aqueous humor outflow. The increased drainage lowers intraocular pressure. Pilocarpine does not reduce aqueous humor production and does not dilate the pupil — it produces miosis through contraction of the iris sphincter.

Question 16

A 34-year-old woman with myasthenia gravis has been well controlled on pyridostigmine for two years. After her neurologist increases her dose, she develops cramping abdominal pain and diarrhea within an hour of each dose. Her muscle strength is unchanged. Which of the following best explains the mechanism producing her gastrointestinal symptoms?

APyridostigmine directly irritates the gastrointestinal mucosa through a local toxic effect
BPyridostigmine activates nicotinic receptors in the enteric nervous system, increasing bowel contractility
CAcetylcholine accumulation at muscarinic receptors on gastrointestinal smooth muscle and secretory cells increases motility and secretion
DPyridostigmine crosses the blood-brain barrier and activates central parasympathetic centers that increase gut motility

Correct Answer

C — Acetylcholine accumulation at muscarinic receptors on gastrointestinal smooth muscle and secretory cells increases motility and secretion

Explanation

Pyridostigmine inhibits acetylcholinesterase at all cholinergic synapses, including postganglionic parasympathetic junctions throughout the gastrointestinal tract. Acetylcholine accumulation at muscarinic receptors on smooth muscle and secretory cells increases intestinal motility and secretion, producing cramping and diarrhea. These dose-dependent muscarinic adverse effects at the gastrointestinal tract occur independently of the drug's therapeutic effect at the neuromuscular junction, which is why her muscle strength is unchanged despite the new symptoms.

Question 17

A 28-year-old woman develops urinary retention two days after an uncomplicated vaginal delivery. She is unable to void despite a palpable bladder. Bladder ultrasound confirms retention without obstruction. Her physician prescribes a direct-acting muscarinic agonist to restore bladder function. Which of the following drugs is most appropriate, and what is its mechanism of action?

APilocarpine — tertiary muscarinic agonist that activates detrusor smooth muscle via muscarinic subtype 3 receptors
BBethanechol — quaternary muscarinic agonist that activates detrusor smooth muscle via muscarinic subtype 3 receptors without central nervous system effects
CNeostigmine — acetylcholinesterase inhibitor that increases acetylcholine at the detrusor neuromuscular junction
DAtropine — muscarinic antagonist that relaxes the urethral sphincter to permit voiding

Correct Answer

B — Bethanechol — quaternary muscarinic agonist that activates detrusor smooth muscle via muscarinic subtype 3 receptors without central nervous system effects

Explanation

Bethanechol is the appropriate choice for non-obstructive urinary retention because it directly activates muscarinic subtype 3 receptors on the detrusor smooth muscle, promoting bladder contraction and voiding. Its quaternary ammonium structure prevents blood-brain barrier crossing, confining its effects to peripheral muscarinic receptors. Pilocarpine is a tertiary amine and would cross into the central nervous system, and its primary indications are glaucoma and xerostomia rather than urinary retention.

Question 18

At the end of a procedure performed under general anesthesia, a patient has residual neuromuscular blockade from rocuronium. The anesthesiologist administers neostigmine together with glycopyrrolate. The patient's muscle strength recovers and heart rate remains stable. Which of the following best explains why this drug combination achieves reversal without bradycardia?

AGlycopyrrolate accelerates neostigmine's displacement of rocuronium from nicotinic receptors at the neuromuscular junction
BGlycopyrrolate blocks nicotinic receptors at the sinoatrial node, preventing the bradycardia that neostigmine would otherwise produce
CNeostigmine and glycopyrrolate compete for the same binding site, slowing acetylcholine accumulation to a rate that avoids bradycardia
DNeostigmine increases acetylcholine at the neuromuscular junction to reverse the blockade, while glycopyrrolate blocks muscarinic M2 receptors at the sinoatrial node to prevent the vagally-mediated bradycardia from acetylcholine accumulation

Correct Answer

D — Neostigmine increases acetylcholine at the neuromuscular junction to reverse the blockade, while glycopyrrolate blocks muscarinic M2 receptors at the sinoatrial node to prevent the vagally-mediated bradycardia from acetylcholine accumulation

Explanation

Neostigmine inhibits acetylcholinesterase throughout the body, increasing acetylcholine at the neuromuscular junction to compete with rocuronium and restore neuromuscular transmission. However, the same acetylcholine accumulation at muscarinic M2 receptors on the sinoatrial node would slow heart rate. Glycopyrrolate, a quaternary muscarinic antagonist with onset matched to neostigmine, blocks M2 receptors at the sinoatrial node and prevents this bradycardia. Because glycopyrrolate cannot cross the blood-brain barrier, it produces no central nervous system effects.